These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24710841)

  • 1. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
    Horenstein RB; Madabushi R; Zineh I; Yerges-Armstrong LM; Peer CJ; Schuck RN; Figg WD; Shuldiner AR; Pacanowski MA
    J Clin Pharmacol; 2014 Aug; 54(8):865-73. PubMed ID: 24710841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
    Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.
    Kim HS; Cho DY; Park BM; Bae SK; Yoon YJ; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    J Clin Pharmacol; 2014 Aug; 54(8):850-7. PubMed ID: 24214141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M; Kajiwara M; Hasegawa S
    J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.
    Wu J; Jia LT; Shao LM; Chen JM; Zhong DD; Xu S; Cai JT
    Eur J Clin Pharmacol; 2013 Feb; 69(2):179-87. PubMed ID: 22706585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.
    Kim KA; Park PW; Hong SJ; Park JY
    Clin Pharmacol Ther; 2008 Aug; 84(2):236-42. PubMed ID: 18323861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
    J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.
    Song BL; Wan M; Tang D; Sun C; Zhu YB; Linda N; Fan HW; Zou JJ
    Clin Ther; 2018 Jul; 40(7):1170-1178. PubMed ID: 30017169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
    Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
    Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
    Collet JP; Hulot JS; Anzaha G; Pena A; Chastre T; Caron C; Silvain J; Cayla G; Bellemain-Appaix A; Vignalou JB; Galier S; Barthélémy O; Beygui F; Gallois V; Montalescot G;
    JACC Cardiovasc Interv; 2011 Apr; 4(4):392-402. PubMed ID: 21511218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
    Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
    Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
    Kitazono T; Ikeda Y; Nishikawa M; Yoshiba S; Abe K; Ogawa A
    J Thromb Thrombolysis; 2018 Nov; 46(4):488-495. PubMed ID: 30074128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.
    Hurbin F; Boulenc X; Daskalakis N; Farenc C; Taylor T; Bonneau D; Lacreta F; Cheng S; Sultan E
    J Clin Pharmacol; 2012 Oct; 52(10):1506-15. PubMed ID: 22128201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
    González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
    Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.